2024 Active Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR24-039 Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | ACTIVE - NOV 18, 2026 |
2023 Active Requests for Applications (RFA's) | |
RFA No. and Title | Status - Expiration |
---|---|
CA23-014 Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | EXPIRED - NOV 18, 2023 |
2023 Active Trans-NIH Requests for Applications (RFA's) | |
RFA No. and Title | Status - Expiration |
---|---|
HG23-033 Advancing Genomic Medicine Research (R21 Clinical Trial Optional) | ACTIVE - FEB 12, 2025 |
OD23-013 Understanding Chronic Conditions Understudied Among Women (R21 Clinical Trial Optional) | ACTIVE - JUN 21, 2024 |
2023 Active Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR23-280 Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | ACTIVE - JAN 08, 2027 |
PAR23-255 Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | ACTIVE - SEP 08, 2026 |
PAR23-152 Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional) | ACTIVE - MAY 08, 2026 |
PAR23-056 Co-infection and Cancer (R21 Clinical Trial Not Allowed) | ACTIVE - NOV 17, 2025 |
2023 Active Trans-NIH Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR23-318 Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) | ACTIVE - MAR 21, 2026 |
PAR23-299 Intervention Research to Improve Native American Health (R21 Clinical Trials Optional) | ACTIVE - JAN 08, 2027 |
PAR23-294 Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | ACTIVE - NOV 19, 2026 |
PAR23-191 HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) | ACTIVE - DEC 09, 2025 |
2022 Active Requests for Applications (RFA's) | |
RFA No. and Title | Status - Expiration |
---|---|
CA22-057 Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | ACTIVE - DEC 16, 2023 |
2022 Active Trans-NIH Requests for Applications (RFA's) | |
RFA No. and Title | Status - Expiration |
---|---|
OD22-007 INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed) | ACTIVE - JUL 02, 2024 |
2022 Active Trans-NIH Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR22-126 Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) | ACTIVE - MAY 08, 2025 |
2021 Active Trans-NIH Requests for Applications (RFA's) | |
RFA No. and Title | Status - Expiration |
---|---|
OD21-007 INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Exploratory/Developmental Research Grant Award (R21 Clinical Trial Not Allowed) | ACTIVE - JUL 04, 2024 |
2021 Active Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR21-341 Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) | ACTIVE - OCT 09, 2024 |
PAR21-332 Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed) | ACTIVE - SEP 08, 2024 |
PAR21-323 Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | ACTIVE - SEP 08, 2024 |
PAR21-061 Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | EXPIRED - NOV 18, 2023 |
2021 Active Trans-NIH Program Announcements (PAs) | |
PA No. and Title | Status - Expiration |
---|---|
PAR21-069 Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) | ACTIVE - JAN 08, 2024 |